AstraZeneca plc (AZN) Price Target Raised to GBX 6,000
AstraZeneca plc (LON:AZN) had its target price boosted by equities research analysts at Jefferies Group from GBX 5,800 ($71.78) to GBX 6,000 ($74.26) in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price objective suggests a potential upside of 21.00% from the stock’s current price.
Several other analysts have also weighed in on the stock. Deutsche Bank AG reiterated a “buy” rating and set a GBX 6,200 ($76.73) target price on shares of AstraZeneca plc in a research note on Tuesday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Monday. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday, October 7th. Credit Suisse Group AG reiterated an “underperform” rating and set a GBX 4,000 ($49.50) target price on shares of AstraZeneca plc in a research note on Friday, October 7th. Finally, Citigroup Inc. reiterated a “buy” rating and set a GBX 6,000 ($74.26) target price on shares of AstraZeneca plc in a research note on Wednesday, October 5th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc has an average rating of “Hold” and an average price target of GBX 4,960.13 ($61.39).
Shares of AstraZeneca plc (LON:AZN) opened at 4958.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The firm’s market cap is GBX 62.73 billion. The company has a 50 day moving average of GBX 5,002.62 and a 200 day moving average of GBX 4,463.11.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/astrazeneca-plc-azn-price-target-raised-to-gbx-6000.html
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.